According to a new report published by Introspective Market Research, titled, Pulmonary Drugs Market by Drug Class, Indication, and Distribution Channel, The Global Pulmonary Drugs Market Size Was Valued at USD 61.10 Billion in 2023 and is Projected to Reach USD 108.60 Billion by 2032, Growing at a CAGR of 6.60%. The Pulmonary Drugs Market is expanding steadily, driven by the rising prevalence of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and lung cancer. Pulmonary drugs play a vital role in managing symptoms, improving lung function, and enhancing the quality of life for millions of patients worldwide.
Compared to traditional treatment approaches, pulmonary drugs offer targeted delivery mechanisms such as inhalers and nebulizers that ensure faster onset of action with minimal systemic side effects. These therapeutic solutions are widely adopted across hospitals, clinics, and retail pharmacies, making them critical in global healthcare systems.
Furthermore, factors such as aging populations, increasing air pollution, and lifestyle-related respiratory complications are fueling demand for effective pulmonary drugs. Pharmaceutical companies are also investing heavily in R&D to introduce novel biologics, biosimilars, and combination therapies, which is expected to accelerate market growth over the forecast period.
One of the primary growth drivers for the Pulmonary Drugs Market is the rising global prevalence of chronic respiratory diseases (CRDs). According to WHO, COPD and asthma collectively affect over 500 million people worldwide, resulting in high demand for effective drug therapies. The increase in environmental pollution, smoking rates, and occupational hazards further accelerates the need for advanced pulmonary drugs. This growing patient population is pushing healthcare providers and pharmaceutical companies to innovate and deliver efficient treatment options, thereby driving consistent market expansion.
The emergence of biologics and targeted therapies presents a significant market opportunity. Biologics such as monoclonal antibodies are gaining traction in treating severe asthma and pulmonary hypertension, where conventional drugs show limited effectiveness. With ongoing advancements in precision medicine and increasing regulatory approvals, biologics are expected to reshape treatment standards. Moreover, the expansion of online pharmacy channels is opening new distribution opportunities, especially in emerging economies, providing patients with improved access to advanced pulmonary drugs at competitive prices.
Pulmonary Drugs Market, Segmentation
Drug Class
- The Drug Class segment is further classified into Bronchodilators, Corticosteroids, Antihistamines, Leukotriene Antagonists, Immunosuppressants, and Others. Among these, the Bronchodilators sub-segment accounted for the highest market share in 2023. Bronchodilators are widely prescribed for asthma and COPD patients as they provide rapid relief by relaxing airway muscles and improving airflow. Their accessibility in multiple forms, including inhalers and nebulizers, coupled with increasing demand for combination therapies, has fueled their dominance. Growing awareness and availability of both short-acting and long-acting bronchodilators contribute significantly to their market share.
Indication
- The Indication segment is further classified into Asthma, COPD, Pulmonary Arterial Hypertension (PAH), and Others. Among these, the Asthma sub-segment accounted for the highest market share in 2023. Asthma affects nearly 300 million people globally, and the prevalence continues to rise due to urbanization, pollution, and genetic predisposition. Pulmonary drugs targeting asthma focus on symptom control and preventing exacerbations, making them a consistent area of demand. Advancements in inhalation therapies, coupled with the rising use of biologics for severe asthma cases, are expected to further boost growth in this segment.
Some of The Leading/Active Market Players Are-
- GlaxoSmithKline plc (United Kingdom)
- AstraZeneca plc (United Kingdom)
- Novartis AG (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Merck & Co., Inc. (United States)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Cipla Limited (India)
- Sanofi (France)
- Mylan N.V. (United States)
- Vertex Pharmaceuticals (United States)
- Chiesi Farmaceutici S.p.A (Italy)
- Sun Pharmaceutical Industries Ltd. (India)
- Roche Holding AG (Switzerland)
- Pfizer Inc. (United States)
- Amgen Inc. (United States)
Key Industry Developments
- In February 2024, AstraZeneca received FDA approval for its biologic therapy targeting severe eosinophilic asthma, expanding its respiratory drug portfolio.
This approval strengthens AstraZeneca’s competitive positioning in the biologics segment and provides patients with advanced therapeutic options. The launch is expected to drive significant adoption in the U.S. and other regulated markets. - In June 2024, GlaxoSmithKline announced a strategic collaboration with a digital health company to enhance smart inhaler technology for asthma and COPD patients.
The partnership focuses on integrating digital monitoring tools with inhalers to improve adherence, track patient usage, and generate real-world evidence, marking a step toward personalized pulmonary care.
Key Findings of the Study
- Bronchodilators dominated the market in 2023 due to their wide application in asthma and COPD treatment.
- Asthma emerged as the leading indication segment globally.
- Rising prevalence of chronic respiratory diseases is the primary growth driver.
- Biologics and digital health integration represent key market trends.
- North America leads the market, while Asia-Pacific shows the fastest growth potential.
